Edition:
United States

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

1.51USD
3:59pm EST
Change (% chg)

$-0.04 (-2.58%)
Prev Close
$1.55
Open
$1.59
Day's High
$1.59
Day's Low
$1.47
Volume
40,618
Avg. Vol
60,561
52-wk High
$6.98
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Pulmatrix posts Q3 net loss of $0.22 per share
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly ‍net loss per share attributable to common stockholders $0.22​.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article

Pulmatrix says generated no revenue in Q2 of 2017
Friday, 4 Aug 2017 08:55am EDT 

Aug 4 (Reuters) - Pulmatrix Inc :Pulmatrix provides 2017 company year-to-date highlights and q2 2017 updated financials.Generated no revenues in Q2 of 2017, compared to $0.3 million for Q2 of 2016.Qtrly loss per share $0.29.Decreased qtrly revenue directly related to conclusion of clinical study funded under collaboration agreement to develop PUR0200 for COPD.As of June 30, 2017, Pulmatrix had $11.0 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article

Pulmatrix reports qtrly loss per share $0.21
Friday, 5 May 2017 08:55am EDT 

May 5 (Reuters) - Pulmatrix Inc : :Pulmatrix reports Q1 2017 financial results.Qtrly loss per share $0.21.Pulmatrix Inc - pulmatrix generated no revenues in Q1 of 2017, compared to $0.4 million for Q1 of 2016.  Full Article

Pulmatrix reports 2016 financial results provides
Friday, 10 Mar 2017 08:55am EST 

Pulmatrix Inc : Pulmatrix reports 2016 financial results; provides 2017 outlook on pulmonary disease pipeline .Pulmatrix inc- intends to seek a pre-ind meeting with FDA to inform U.S. Clinical development path for pur0200 in second half of 2017.  Full Article

FDA grants orphan drug status to Pulmatrix's PUR1900
Wednesday, 17 Aug 2016 01:23pm EDT 

Pulmatrix Inc : Pulmatrix receives orphan drug designation from the FDA for inhaled drug to treat pulmonary fungal infections in cystic fibrosis patients .FDA granted co's request for orphan drug status for drug for treating pulmonary fungal infections in cystic fibrosis patients, named PUR1900.  Full Article

Pulmatrix reports quarterly loss per share $0.62
Thursday, 4 Aug 2016 08:30am EDT 

Pulmatrix Inc : Quarterly loss per share $0.62 .Revenues for Q2 of 2016 were $0.3 million, compared to $0.2 million for Q2 of 2015.  Full Article

Pulmatrix and Mylan collaborate for pilot pharmacokinetic clinical study
Tuesday, 19 Jul 2016 08:30am EDT 

Pulmatrix Inc : Pulmatrix led pilot pharmacokinetic clinical study and supportive development work with collaborative support from Mylan . Financial terms of agreement are confidential . Announced positive topline data from a phase 1 pilot pharmacokinetic bioavailability trial of PUR0200 .Mylan has retained an option for PUR0200 EX-U.S. rights based on successful completion of clinical study.  Full Article

Pulmatrix Inc files for mixed shelf of upto $30 mln
Friday, 15 Jul 2016 05:03pm EDT 

Pulmatrix Inc :Pulmatrix Inc files for mixed shelf of upto $30 mln - SEC filing.  Full Article

Capsugel, Pulmatrix enter collaboration to develop, manufacture novel inhaled therapeutics
Tuesday, 16 Feb 2016 08:00am EST 

Pulmatrix Inc:Capsugel and Pulmatrix enter collaboration to develop and manufacture novel inhaled therapeutics.Agreement gives capsugel rights to manufacture clinical trial and commercial batches of Isperse(TM)-based inhaled therapeutic candidates.Capsugel will combine spray drying process development, scale-up expertise commercial manufacturing capabilities with pulmatrix's isperse.  Full Article

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials